These DCs contained several specific tumor-associated antigenic determinant genes, including carcinoembryonic antigen (CEA), cytokeratin 19 (CK19), and prostate specific membrane antigen (PSMA), highlighting the potential of ACT therapies in treating BrM (Priceman et al., 2018; Wang et al., 2020). This evidence concerns the gene KRT19 and neoplasm.